Results 91 to 100 of about 29,614 (185)

A novel hybrid method with convergence analysis for approximation of HTLV-I dynamics model. [PDF]

Sci Rep
Molavi-Arabshahi M, Rashidinia J, Yousefi M.   +2 more
europepmc   +1 more source

Evaluation of Elecsys HTLV-I/II assay in comparison with ARCHITECT rHTLV-I/II assay with Korean samples. [PDF]

J Clin Lab Anal, 2019
Yun SG, Kim SW, Sohn JY, Cho Y.
europepmc   +1 more source

The HTLV-I oncoprotein Tax inactivates the tumor suppressor FBXW7. [PDF]

J Virol
Bellon M, Yeh C-h, Bai XT, Nicot C.
europepmc   +1 more source

NF-κB1 deficiency promotes macrophage-derived adrenal tumors but decreases neurofibromas in HTLV-I LTR-Tax transgenic mice. [PDF]

PLoS One
Song X, Qu Z.
europepmc   +1 more source

Clinical and laboratory features of HTLV-I asymptomatic carriers and patients with HTLV-I-associated myelopathy/tropical spastic paraparesis from the Brazilian Amazon. [PDF]

Rev Inst Med Trop Sao Paulo, 2017
Takatani M, Crispim ME, Fraiji N, Stefani MM, Kiesslich D.   +4 more
europepmc   +1 more source

Therapeutic Approaches for HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis: Current and Emerging Strategies. [PDF]

Pathogens
Nakamura T, Satoh K.
europepmc   +1 more source

From serologic uncertainty to diagnostic clarity in unusual adult T-cell leukemia/lymphoma via HBZ in situ hybridization. [PDF]

J Hematop
Cheverez-Ocasio J, Medeiros LJ, Tashakori M.   +2 more
europepmc   +1 more source

Heterogeneity of HTLV-1 proviral integration sites and internal structures in the ATL cell line MT-1. [PDF]

Hum Cell
Izaki M, Hashikura Y, Umekita K, Umeki K, Miyazaki T.   +4 more
europepmc   +1 more source

The challenge of HTLV-1 therapeutics: lessons from anti-protease approaches. [PDF]

New Microbes New Infect
Ahmadi Ghezeldasht S, Miri R, Shamsian SK, Mosavat A, Rezaee SA.   +4 more
europepmc   +1 more source